Patients Undergoing Operative Fixation of Long Bone Fractures Within the Community Medical Centers System
Conditions
Keywords
TXA, Anticoagulant, Orthopaedic Trauma
Brief summary
Tranexamic acid, an anti-fibrinolytic agent, is commonly given after induction of general anesthesia in patients undergoing hip and knee arthroplasty. This medication has been associated with decreased blood loss during these procedures, decreased rate of blood transfusion, decreased hospital costs, and no increased risk of thrombotic complication. Given the safety and efficacy of this medication in one subspeciality of orthopedics, it is warranted to investigate the use of it in another subspeciality where blood loss is also of concern. It is also of the utmost importance to identify medications that can safely be given to our population to not only improve patient outcomes but also decrease patient costs in the setting of significant disparities. The application of these findings to orthopedic trauma is not something that has been largely studied or appears in the literature. We hope to fill this gap of knowledge to allow for the application of a safe and beneficial medication to a much larger subset of patients than that that is already receiving the medication routinely. The use of TXA in orthopedic patients who are on anticoagulation versus those who are not is also not something that has been previously studied and another knowledge gap that we hope to fill.
Interventions
DRUGTranexamic Acid (TXA)
orthopedic trauma patients who are on anticoagulation
Sponsors
Arbi Nazarian, MD
Inspire Health Medical Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients undergoing operative fixation of long bone fractures; Included conditions include femoral neck fractures, intertrochanteric femur fractures, femoral shaft fractures, distal femur fractures, and tibial shaft fractures that undergo surgical management
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimated blood loss (EBL) comparison between those who received TXA vs no TXA | EBL note is made post-procedure by surgical team, and research team will collect data at least one month post-procedure | Less estimated blood loss after surgery for patients who were administered TXA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital Length of Stay for Patients who received TXA vs no TXA | EBL note is made post-procedure by surgical team, and research team will collect data at least one month post-procedure | Patient medical records will be reviewed post-operatively and data will be collected in our study specific data sheet. |
Countries
United States
Contacts
CONTACTYeng Vue, MA
CONTACTMolly Mounsey, MD
PRINCIPAL_INVESTIGATORArbi Nazarian, MD
University of California, San Francisco
Outcome results
None listed